SB0298_SUPPORT_HEAU_O'Connor.pdfUploaded by: O'Connor, Patricia

Position: FAV

BRIAN E. FROSH Attorney General

ELIZABETH F. HARRISChief Deputy Attorney General

CAROLYN QUATTROCKI
Deputy Attorney General

Writer's Direct Fax No. (410) 576-6571

Writer's Direct Email: poconnor@oag.state.md.us



WILLIAM D. GRUHN

Chief

Consumer Protection Division

STATE OF MARYLAND OFFICE OF THE ATTORNEY GENERAL CONSUMER PROTECTION DIVISION

Writer's Direct Dial No. (410) 576-6515

January 22, 2021

To: The Honorable Paul G. Pinsky

Chair, Education, Health and Environmental Affairs Committee

From: Patricia F. O'Connor, Health Education and Advocacy Unit

Re: Senate Bill 298 (State Board of Pharmacy – Pharmacy Closure – Notice to

Customers (The Dennis Robin Act): Support

The Office of the Attorney General's Health Education and Advocacy Unit (HEAU) supports Senate Bill 298 which would expressly require pharmacies that are planning to close to provide advance notice directly to customers before closing. The Maryland Board of Pharmacy currently has regulations that govern pharmacy closures but the regulations do not require direct advance notice to customers. We believe the bill would improve protections for consumers against abrupt closures without notice, or those occurring with inadequate notice to consumers. The notice is critical for customers needing to find alternate pharmacies to fill prescriptions.

We urge the Committee to give the bill a favorable report.

cc: Sponsor

SB 298-2021-IPMD-2.pdf Uploaded by: Doyle, James Position: FWA

SB 298

State Board of Pharmacy-Pharmacy Closure-Notice to Customers

Position of: **Independent Pharmacies of MD (IPMD)**

Position: FAVORABLE WITH AMENDMENTS

WHAT THE BILL DOES:

The bill requires that the owner of a pharmacy post a notice of an anticipated closure of a

pharmacy at least 30 days before closure, or by mail at least 14 days to each customer that has a

current or authorized refill on file with the pharmacy.

WHY THE BILL SHOULD BE AMENDED:

In most cases, pharmacies close as a result of a sale to another pharmacy. As a part of that sale,

the pharmacy will transfer prescriptions to the acquiring pharmacy. The sale price reflects the

amount of revenue generated by the pharmacy, as well as future revenues. In the case of

independent pharmacies, most of its revenue is generated through prescriptions, so any impact on

the number of prescriptions to be transferred will have a significant impact on the sales price.

In most sales contracts for the business, there will be a "true-up" or some other process that will

adjust the initial contract sales price to a price at the time of closing to reflect actual revenues at

that time. If the pharmacy loses 5 % or 10% of its prescriptions, e.g., between the signing of the

contract and the time of closing, there will likely be a contract adjustment and a corresponding

reduction of the sales price.

IPMD does not object to the concept of notice to a consumer that a pharmacy is closing, and

notice that its prescriptions will be transferred. But independent pharmacies, in particular, are

under financial stress. So, the time for that notice should be reasonable so that the pharmacy does

not potentially suffer a substantial loss in the value of its operation just before closing of the sale. IPMD believes that a 10-day posted notice requirement at the closing pharmacy would be sufficient, and would allow customers who want to move their prescriptions before closure the opportunity to do so. And a mail notice option by the selling pharmacy is unnecessary and should be eliminated; the acquiring pharmacy has the incentive to, and will, notify its new customers of the transfers in order to retain their business. We believe that these amendments correctly balance the interests of the closing pharmacy and its customers.

PROPOSED AMENDMENTS:

Change the time limit for a posted notice from 30 days to 10 days.

Eliminate any mailing notice option, (or, in the alternative, specify that any mailing notice is to be done by the acquiring pharmacy).

Contact:

James J. Doyle

Jimdoyle3@comcast.net

443-676-2940